Concert Pharmaceuticals has received US patent for CTP-499, its drug candidate being developed for the treatment of diabetic nephropathy. CTP-499 is a potential treatment developed on the basis of DCE Platform for diabetic nephropathy, a ...
Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office. The patent covers the synergistic effects of combination therapies containing COTI-2 and members of ...
Tags: oncology drug, COTI-2, anti cancer agents
Ironwood Pharmaceuticals, Bionomics' licensee, has submitted an investigational new drug (IND) application to the FDA to begin IW-2143 clinical trial. The trial will further evaluate pharmacokinetic profile of the anti-anxiety drug ...
Kaneka has unveiled KANEKA KanCapA, a new protein A chromatography resin to purify therapeutic antibodies. Protein A chromatography resin is widely used to produce antibodies due to its high affinity and excellent selectivity for ...
CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m. Upon successful continued clinical development of PRO ...
Tags: CytoDyn, HIV viral-entry inhibitor drug, humanized monoclonal antibody
Synergy Pharmaceuticals has signed an asset purchase agreement to acquire FV-100 shingles drug from Bristol-Myers Squibb Company. FV-100 is an orally available nucleoside analogue, at present being developed for the treatment of shingles, ...
Tags: Synergy Pharmaceuticals, treatment of shingles, FV-100
The European Commission (EC) has granted a €6m grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501. The FIGHT HLH consortium lead by NovImmune ...
Cara Therapeutics and Chong Kun Dang Pharmaceutical have signed licensing contract to develop and market CR845, an analgesic drug candidate, in the Republic of Korea. As a part of the agreement, Cara is eligible to gain an up-front ...
Tags: analgesic drug candidate, licensing contract, CR845, Cara Therapeutics
Galapagos, a mid-size biotechnology company, has delivered the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. Servier and Galapagos entered into an alliance in July 2010 to develop new oral medicines ...
Tags: Galapagos Identifies Drug, Galapagos, Servier, osteoarthritis
The US Patent and Trademark Office (USPTO) has granted three new patents to A.P. Pharma's new APF530 drug delivery candidate. The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset ...
Tags: US Patent, A.P.Pharma, APF530 drug delivery candidate, New Drug Delivery
Biogen Idec (BIIB) and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement, pursuant to which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic ...
Tags: Steinert Disease, antisense drug
Clinical-stage biopharmaceutical company OXiGENE's acute myelogenous leukemia (AML) drug candidate, OXi4503, has received FDA orphan drug status. The second-generation anticancer agent with a dual-mechanism vascular disrupting feature ...
Basilea Pharmaceutica has commenced next pharmacokinetic Phase 1 study with antibiotic BAL30072 in healthy volunteers. The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to ...
Cyprotex has signed a new licensing agreement with Sigma Life Science to add CompoZr Zinc Finger Nuclease technology to its screening services. Sigma Life Science has applied its exclusive CompoZr Zinc Finger Nuclease technology to the ...
RayBiotech, a developer of antibody and protein array technologies, has introduced a peptoid drug candidate and diagnostic ligand discovery service program. The new service platform, which is aimed at the identification of novel ligands ...
Tags: rayBiotech, peptoid, ligand, peptoid drug candidate